Casa Di Cura Igea S.p.A.
- Address
- Via Giuseppe Dezza 48, 20144 Milan, Italy
Casa Di Cura Igea S.p.A. - Neurological Disorders Research Center
Casa Di Cura Igea S.p.A. is a distinguished clinical research facility specializing in advanced therapeutic investigations for complex neurological and neurodegenerative disorders. The center demonstrates particular expertise in conducting sophisticated pharmacokinetic and pharmacodynamic studies, as well as evaluating novel biologics and therapeutic agents for conditions affecting the central and peripheral nervous systems.
- Multiple sclerosis research, including biosimilar comparability studies and relapsing-remitting disease management
- Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment investigations with innovative immunomodulatory agents
- Alzheimer's disease clinical trials focusing on cognitive preservation in mild to moderate dementia
The center's research portfolio reflects a comprehensive approach to autoimmune neurological conditions and neurodegenerative diseases, with particular emphasis on randomized, double-blind, placebo-controlled trial designs. Their involvement in multinational biosimilar development programs and novel therapeutic evaluations positions them as a key contributor to advancing treatment options for patients with debilitating neurological disorders, while maintaining rigorous safety and efficacy assessment standards.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Amgen Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Casa Di Cura Igea S.p.A.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Study of Pharmacokinetics, Pharmacodynamics, and Safety of ABP 692 and Ocrelizumab in Relapsing-Remitting Multiple Sclerosis | Amgen Inc. | Phase III | Not Yet Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Human Normal Immunoglobulin | 1 | Unknown | 2022-10-24 | 2022-10-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.